Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.
Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade therapy is a new class of anticancer immunotherapy that utilizes the body’s immune system to resist cancer and causes cancer cell death by blocking the PD-1/PD-L1 signaling pathway.
Download this whitepaper to learn more about PD-1/PD-L1:
- Blockade therapy resistance
- Combination therapy with CTLA-4 blockers
- Combination therapy with targeted drug EGFR